Hello, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that familiar routine of meetings, deadlines, and the like has returned. You knew this would happen, though, yes? What else can one do but cope by firing up the coffee kettle for a few cups of stimulation. Our choice today is old-fashioned cinnamon latte in the event you are looking for ideas. Meanwhile, here are a few items of interest to help you along. Hope your journey is rewarding and, as always, do keep in touch …
GlaxoSmithKline (GSK) is facing “unprecedented” demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought, Reuters informs us. More than 1.5 million Americans have received Shingrix since the end of last year, but U.S. health officials have warned of shortages. Meanwhile, analysts currently forecast peak annual sales of around $2 billion but this could be doubled, according to Exane BNP if Shingrix can achieve market penetration rates of around 60 percent.
About the Author Reprints
